Last Updated: 04/06/07
In Vivo Cancer Imaging Exploratory/Development Grants
Program Announcement:
PA-04-045:
http://grants.nih.gov/grants/Guide/pa-files/PA-04-045.html(expiration date extended to 11/2/2006)
Contact:
Anne E. Menkens, Ph.D.
301-435-9024, menkensa@mail.nih.gov
Innovative in vivo cancer imaging applications have an expanding potential to improve the detection and diagnosis of cancer and alter the clinical management of cancer patients. This CIP initiative provides investigators at all career levels with a level of funding adequate for the initial feasibility testing of high-risk/high-impact cancer imaging concepts and generation of experimental preliminary data. Investigators from other scientific disciplines who wish to apply and integrate new imaging reagents and technologies in unique ways are also eligible for this R21 exploratory/developmental grant program, which provides nonrenewable funding for up to two years. This CIP program has been available to investigators since 1999 and was recently approved for an additional three-year reissuance. Each release of this continuing series of announcements has responded to changes in the field of imaging. In the newest announcement, additional emphasis is placed on the development and application of imaging agents and methodologies to monitor response to therapy.
The CIP projects funded through this mechanism have precedent-setting potential in new areas of in vivo cancer imaging.
This program has supported research at every end of the discovery-development-delivery continuum for imaging— from the synthesis and early development of novel imaging agents to development of cutting-edge imaging hardware and software and a number of pilot-phase clinical studies. Topics have included innovative in vivo cancer imaging technologies, novel agents to detect cancerous and precancerous processes, methods to display and analyze in vivo images, and image-guided treatments of cancer.
A review of 95 grants funded in fiscal years 1999 through 2003 reveals that 32, or 34 percent, have successfully transitioned to larger NIH-funded programs.
